Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 48 of the 50 references it cites were found in a registry or an index; 15 of the 54 sources its claims cite were checked for support.

Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial

Open access

Abstract

Retatrutide is a novel triple agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1 and glucagon receptors. A 48-week phase 2 obesity study demonstrated weight reductions of 22.8% and 24.2% with retatrutide 8 and 12 mg, respectively. The primary objective of this substudy was to assess mean relative change from baseline in liver fat (LF) at 24 weeks in participants from that study with metabolic dysfunction-associated steatotic liver disease and ≥10% of LF. Here, in this randomized, double-blind, placebo-controlled trial, participants (n = 98) were randomly assigned to 48 weeks of once-weekly subcutaneous retatrutide (1, 4, 8 or 12 mg dose) or placebo. The mean relative change from baseline in LF at 24 weeks was -42.9% (1 mg), -57.0% (4 mg), -81.4% (8 mg), -82.4% (12 mg) and +0.3% (placebo) (all P < 0.001 versus placebo). At 24 weeks, normal LF (<5%) was achieved by 27% (1 mg), 52% (4 mg), 79% (8 mg), 86% (12 mg) and 0% (placebo) of participants. LF reductions were significantly related to changes in body weight, abdominal fat and metabolic measures associated with improved insulin sensitivity and lipid metabolism. The ClinicalTrials.gov registration is NCT04881760 .

Overview

CoChat Summary

## TL;DR

This randomized phase 2a substudy found that once-weekly retatrutide substantially reduced liver fat in participants with MASLD over 24 weeks, with the largest effects at 8 mg and 12 mg. The paper reports that more than 85% of participants in the two highest-dose groups achieved liver fat <5% by 24 and 48 weeks.

## Key findings

  • In 98 randomized participants with MASLD and liver fat ≥10% by MRI-PDFF, mean relative liver fat change at 24 weeks was −42.9% (1 mg), −57.0% (4 mg), −81.4% (8 mg), and −82.4% (12 mg), versus +0.3% with placebo; all were P < 0.001 versus placebo.
  • At 24 weeks, normal liver fat (<5%) was achieved by 27% (1 mg), 52% (4 mg), 79% (8 mg), and 86% (12 mg), versus 0% with placebo.
  • At 48 weeks, relative liver fat change remained large: −51.3%, −59.0%, −81.7%, and −86.0% for 1, 4, 8, and 12 mg, versus −4.6% with placebo; all doses were superior to placebo (P < 0.001).
  • Retatrutide also reduced body weight and abdominal fat: at 48 weeks, body weight changed by −8.6%, −16.3%, −23.8%, and −25.9% across the 1, 4, 8, and 12 mg doses, and VAT/ASAT were significantly reduced versus placebo.

## Methods

  • Randomized, double-blind, placebo-controlled phase 2a substudy of a 48-week multicenter obesity trial; participants received once-weekly subcutaneous retatrutide (1, 4, 8, or 12 mg) or placebo.
  • The MASLD substudy included 98 participants from the parent trial who had MASLD and liver fat content ≥10% by MRI-PDFF; the main study randomized 338 participants total.
  • Primary outcome was relative liver fat change at 24 weeks by MRI-PDFF; secondary/exploratory outcomes included 48-week liver fat, body weight, waist circumference, VAT/ASAT, metabolic biomarkers, and MASH/fibrosis biomarkers, analyzed with mixed models for repeated measures and logistic regression.

## Limitations

  • The paper states the substudy had a relatively small sample size, was geographically and racially homogeneous (United States only, majority white), excluded patients with type 2 diabetes, lacked liver histology, lacked enrichment for MASH or significant fibrosis, and had no multiplicity control for many statistical tests.
  • The paper states that 48-week MRI data were unavailable for 56.1% of participants, limiting interpretation of the 48-week dose-response for liver fat reduction.
  • Evident from the text: this was a substudy within an obesity trial, so the MASLD cohort may not represent broader MASLD populations.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41591-024-03018-2

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Change in liver fat. a, Relative liver fat reduction. Results are shown as LSM ± s.e.m. (n = 19 (PBO), n = 20 (1 mg RETA), n = 19 (4 mg RETA), n = 22 (8 mg RETA) and n = 18 (12 mg RETA)). b, The percentage of participants achieving liver fat reduction targets at week 24. c, The percentage of participants achieving liver fat content <5%. Comparisons versus PBO were done by using two-sided z-tests without multiplicity adjustment. *P < 0.05 versus PBO; ***P < 0.001 versus PBO; #, not calculable. Fewer participants had MRIs at week 48 (n = 8 (PBO), n = 9 (1 mg RETA), n = 9 (4 mg RETA), n = 8 (8 mg RETA) and n = 9 (12 mg RETA)) compared with week 24 (n = 14 (PBO), n = 16 (1 mg RETA), n = 15 (4 mg RETA), n = 17 (8 mg RETA) and n = 15 (12 mg RETA)).
Fig. 1 Change in liver fat. a, Relative liver fat reduction. Results are shown as LSM ± s.e.m. (n = 19 (PBO), n = 20 (1 mg RETA), n = 19 (4 mg RETA), n = 22 (8 mg RETA) and n = 18 (12 mg RETA)). b, The percentage of participants achieving liver fat reduction targets at week 24. c, The percentage of participants achieving liver fat content <5%. Comparisons versus PBO were done by using two-sided z-tests without multiplicity adjustment. *P < 0.05 versus PBO; ***P < 0.001 versus PBO; #, not calculable. Fewer participants had MRIs at week 48 (n = 8 (PBO), n = 9 (1 mg RETA), n = 9 (4 mg RETA), n = 8 (8 mg RETA) and n = 9 (12 mg RETA)) compared with week 24 (n = 14 (PBO), n = 16 (1 mg RETA), n = 15 (4 mg RETA), n = 17 (8 mg RETA) and n = 15 (12 mg RETA)).CC BY · PubMed Central
Fig. 2 Scatter plot and fitted power model curve. a, Relative liver fat reduction versus percentage changes in body weight at week 48. b, Relative liver fat reduction versus percentage change in waist circumference at week 48. c, Relative liver fat reduction versus percentage change in visceral adipose tissue at week 48. d, Relative liver fat reduction versus percentage changes in abdominal subcutaneous adipose tissue at week 48.
Fig. 2 Scatter plot and fitted power model curve. a, Relative liver fat reduction versus percentage changes in body weight at week 48. b, Relative liver fat reduction versus percentage change in waist circumference at week 48. c, Relative liver fat reduction versus percentage change in visceral adipose tissue at week 48. d, Relative liver fat reduction versus percentage changes in abdominal subcutaneous adipose tissue at week 48.CC BY · PubMed Central
Fig. 3 Percent change in abdominal adipose tissue depots. a, Percentage change in visceral adipose tissue volume (liters). b, Percentage change in abdominal subcutaneous adipose tissue volume (liters). Data are LSMs ± s.e.m. Comparisons versus PBO were done by using two-sided z-tests without multiplicity adjustment. ***P < 0.001 versus PBO.
Fig. 3 Percent change in abdominal adipose tissue depots. a, Percentage change in visceral adipose tissue volume (liters). b, Percentage change in abdominal subcutaneous adipose tissue volume (liters). Data are LSMs ± s.e.m. Comparisons versus PBO were done by using two-sided z-tests without multiplicity adjustment. ***P < 0.001 versus PBO.CC BY · PubMed Central
Fig. 4 Percentage change in K-18 and pro-C3. a, The percentage change in K-18. b, The percentage change in pro-C3 with results shown as LSMs ± s.e.m. Comparisons versus PBO were done by using two-sided z-tests without multiplicity adjustment. *P < 0.05 versus PBO; ***P < 0.001 versus PBO. Pro-C3 measured with the second-generation ELISA corrected to correspond to the first-generation ELISA to enable comparisons to published literature (correction factor of 0.152).
Fig. 4 Percentage change in K-18 and pro-C3. a, The percentage change in K-18. b, The percentage change in pro-C3 with results shown as LSMs ± s.e.m. Comparisons versus PBO were done by using two-sided z-tests without multiplicity adjustment. *P < 0.05 versus PBO; ***P < 0.001 versus PBO. Pro-C3 measured with the second-generation ELISA corrected to correspond to the first-generation ELISA to enable comparisons to published literature (correction factor of 0.152).CC BY · PubMed Central
Extended Data Fig. 1 Study design and trial disposition. Top: patient disposition (CONSORT diagram) of the substudy. Completion of the substudy refers to completing the study visits, including the safety follow-up period, irrespective of adherence to study treatment. Participants who completed treatment stayed on study treatment for the treatment period. Bottom: study design schema with MRI/MASH biomarker schedule. Where applicable, dose escalations occurred every 4 weeks.
Extended Data Fig. 1 Study design and trial disposition. Top: patient disposition (CONSORT diagram) of the substudy. Completion of the substudy refers to completing the study visits, including the safety follow-up period, irrespective of adherence to study treatment. Participants who completed treatment stayed on study treatment for the treatment period. Bottom: study design schema with MRI/MASH biomarker schedule. Where applicable, dose escalations occurred every 4 weeks.CC BY · PubMed Central
Extended Data Fig. 2 Participant-level changes in liver fat. Data for all participants is shown, excluding data after discontinuation of treatment. One of the participants in the 8 mg dose group missed the last two doses of retatrutide, despite being marked as treatment completed by the investigator. This may have contributed to the lesser relative liver fat reduction at week 48 (−68.5%) compared with week 24 (−84.5%) for this participant.
Extended Data Fig. 2 Participant-level changes in liver fat. Data for all participants is shown, excluding data after discontinuation of treatment. One of the participants in the 8 mg dose group missed the last two doses of retatrutide, despite being marked as treatment completed by the investigator. This may have contributed to the lesser relative liver fat reduction at week 48 (−68.5%) compared with week 24 (−84.5%) for this participant.CC BY · PubMed Central
Extended Data Fig. 3 Percent of participants achieving liver fat reduction targets at week 48. Results shown as LS means ± SE. Comparisons vs. PBO were done by using 2-sided z-tests without multiplicity adjustment. Fewer participants had MRIs at Week 48 (n=8 [PBO], n=9 [1 mg RETA], n=9 [4 mg RETA], n=8 [8 mg RETA], n=9 [12 mg RETA]) compared with Week 24 (n=14 [PBO], n=16 [1 mg RETA], n=15 [4 mg RETA], n=17 [8 mg RETA], n=15 [12 mg RETA]). MRI, magnetic resonance imaging; PBO, placebo; RETA, retatrutide.
Extended Data Fig. 3 Percent of participants achieving liver fat reduction targets at week 48. Results shown as LS means ± SE. Comparisons vs. PBO were done by using 2-sided z-tests without multiplicity adjustment. Fewer participants had MRIs at Week 48 (n=8 [PBO], n=9 [1 mg RETA], n=9 [4 mg RETA], n=8 [8 mg RETA], n=9 [12 mg RETA]) compared with Week 24 (n=14 [PBO], n=16 [1 mg RETA], n=15 [4 mg RETA], n=17 [8 mg RETA], n=15 [12 mg RETA]). MRI, magnetic resonance imaging; PBO, placebo; RETA, retatrutide.CC BY · PubMed Central
Extended Data Fig. 4 Percent change in liver volume. Results shown graphically as LS means ± 1.96 × SE. Comparisons vs. PBO were done by using 2-sided z-tests without multiplicity adjustment. LS – least square; SE – standard error; PBO – placebo; RETA – retatrutide; *p<0.05 vs. PBO; **p<0.01; ***p<0.001 vs. PBO.
Extended Data Fig. 4 Percent change in liver volume. Results shown graphically as LS means ± 1.96 × SE. Comparisons vs. PBO were done by using 2-sided z-tests without multiplicity adjustment. LS – least square; SE – standard error; PBO – placebo; RETA – retatrutide; *p<0.05 vs. PBO; **p<0.01; ***p<0.001 vs. PBO.CC BY · PubMed Central
Extended Data Fig. 5 Percentage change in body weight and waist circumference. a, The percentage change in body weight. b, The percentage change in waist circumference with results shown as LS means (SE). Comparisons vs. PBO were done by using 2-sided z-tests without multiplicity adjustment. *p<0.05 vs. PBO; **p<0.01; ***p<0.001 vs. PBO. Results at the 48-week end-of-treatment visit are shown with statistical testing results. Additionally, 4-week post-treatment results are shown. LS, least squares; PBO, placebo; RETA, retatrutide; SE, standard error.
Extended Data Fig. 5 Percentage change in body weight and waist circumference. a, The percentage change in body weight. b, The percentage change in waist circumference with results shown as LS means (SE). Comparisons vs. PBO were done by using 2-sided z-tests without multiplicity adjustment. *p<0.05 vs. PBO; **p<0.01; ***p<0.001 vs. PBO. Results at the 48-week end-of-treatment visit are shown with statistical testing results. Additionally, 4-week post-treatment results are shown. LS, least squares; PBO, placebo; RETA, retatrutide; SE, standard error.CC BY · PubMed Central
Extended Data Fig. 6 FGF21 percentage change from baseline. Results shown are LS means (SE). Comparisons vs. PBO were done by using 2-sided z-tests without multiplicity adjustment. *p<0.05 vs. PBO; **p<0.01; ***p<0.001 vs. PBO. FGF21, fibroblast growth factor 21; LS, least squares; PBO, placebo; RETA, retatrutide; SE, standard error.
Extended Data Fig. 6 FGF21 percentage change from baseline. Results shown are LS means (SE). Comparisons vs. PBO were done by using 2-sided z-tests without multiplicity adjustment. *p<0.05 vs. PBO; **p<0.01; ***p<0.001 vs. PBO. FGF21, fibroblast growth factor 21; LS, least squares; PBO, placebo; RETA, retatrutide; SE, standard error.CC BY · PubMed Central
Extended Data Fig. 7 Percent change from baseline - ALT and AST. a, The percentage change from baseline in ALT. b, The percentage change from baseline in AST with results shown graphically as LS means ± 1.96 × SE; Baseline as geometric mean (Coefficient of variation%). Comparisons vs. PBO were done by using 2-sided z-tests without multiplicity adjustment. ALT=alanine aminotransferase; AST=aspartate aminotransferase; LS=least squares; PBO=placebo; RETA= retatrutide; SE=standard error.
Extended Data Fig. 7 Percent change from baseline - ALT and AST. a, The percentage change from baseline in ALT. b, The percentage change from baseline in AST with results shown graphically as LS means ± 1.96 × SE; Baseline as geometric mean (Coefficient of variation%). Comparisons vs. PBO were done by using 2-sided z-tests without multiplicity adjustment. ALT=alanine aminotransferase; AST=aspartate aminotransferase; LS=least squares; PBO=placebo; RETA= retatrutide; SE=standard error.CC BY · PubMed Central
Extended Data Fig. 8 Evaluation of drug-induced serious hepatotoxicity (eDISH) plots. a, eDISH plot for MASLD substudy population (n=98). b, eDISH plot for overall obesity population (n=336). eDISH, evaluation of Drug-Induced Serious Hepatotoxicity; RETA, retatrutide; ULN, upper limit of normal. Notes on interpretation of the eDISH plot48. ● Hy’s Law refers to the increased risk of serious drug-induced liver injury that is present when both aminotransferase elevations (>3 times the upper limit of the normal range [ULN]) and total bilirubin elevations (>2 times the ULN) occur together. This is denoted by the upper right quadrant of the eDISH plot. ● Temple’s corollary refers to the observation that drugs which caused a marked preponderance of lesser liver injuries compared with control agents, shown by more frequent serum aminotransferase elevations, were more likely to show more Hy’s Law cases. This is denoted by the lower right quadrant of the eDISH plot. ● The upper left quadrant refers to the cholestasis range. ● The lower left quadrant includes values within or near the reference range.
Extended Data Fig. 8 Evaluation of drug-induced serious hepatotoxicity (eDISH) plots. a, eDISH plot for MASLD substudy population (n=98). b, eDISH plot for overall obesity population (n=336). eDISH, evaluation of Drug-Induced Serious Hepatotoxicity; RETA, retatrutide; ULN, upper limit of normal. Notes on interpretation of the eDISH plot48. ● Hy’s Law refers to the increased risk of serious drug-induced liver injury that is present when both aminotransferase elevations (>3 times the upper limit of the normal range [ULN]) and total bilirubin elevations (>2 times the ULN) occur together. This is denoted by the upper right quadrant of the eDISH plot. ● Temple’s corollary refers to the observation that drugs which caused a marked preponderance of lesser liver injuries compared with control agents, shown by more frequent serum aminotransferase elevations, were more likely to show more Hy’s Law cases. This is denoted by the lower right quadrant of the eDISH plot. ● The upper left quadrant refers to the cholestasis range. ● The lower left quadrant includes values within or near the reference range.CC BY · PubMed Central

Verification

Claims the paper makes

13 Valid · 2 Not valid · 21 Not checked · 116 Own results and interpretations

76 more claims · 2 with their cited sources checked

Create a free account to see all 152 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 32
  • It may state two separate claims as one. 53

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

17 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 50 references

Cited by

See all 315

Metadata

Authors
Sanyal, A. J., Kaplan, L. M., Frias, J. P., Brouwers, B., Wu, Q., Thomas, M. K., Harris, C., Schloot, N. C., Du, Y., Mather, K. J., Haupt, A., & Hartman, M. L.
Affiliations
  • Virginia Commonwealth University (US)
  • Dartmouth College (US)
  • Eli Lilly (United States) (US)
  • Eli Lilly (Germany) (DE)
Corresponding author
Sanyal, Arun J.
Venue
Nature Medicine
Published
2024-06-10
Volume
30
Issue
7
Pages
2037-2048
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4399500327
Cited by
315
References
50
Citations by year
2026: 152 · 2025: 137 · 2024: 26
FWCI
95.49
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
Eli Lilly and Company
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
retatrutide, non-alcoholic fatty liver disease, liver fat reduction, glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, glucagon receptor, obesity, insulin sensitivity, lipid metabolism, weight loss, abdominal fat
MeSH terms
Glucagon-Like Peptide-1 Receptor Agonists, Adult, Aged, Double-Blind Method, Fatty Acids, Fatty Liver, Female, Humans, Liver, Male, Middle Aged, Obesity, Peptides, Receptors, Glucagon

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. https://app.cochat.ai/papers/10.1038/s41591-024-03018-2
The paper
Sanyal, A. J., Kaplan, L. M., Frias, J. P., Brouwers, B., Wu, Q., Thomas, M. K., Harris, C., Schloot, N. C., Du, Y., Mather, K. J., Haupt, A., & Hartman, M. L. (2024). Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. https://doi.org/10.1038/s41591-024-03018-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.